MapLight Therapeutics (MPLT) Interest Expenses (2024 - 2026)

MapLight Therapeutics (MPLT) posted Interest Expenses of $300000.0 for Q4 2025, down 92.72% sequentially from $4.1 million in Q3 2025, and up 200.0% YoY from $100000.0 in Q4 2024.

MapLight Therapeutics (MPLT) Interest Expenses (2024 - 2026) Analysis & Trends

MapLight Therapeutics has reported Interest Expenses for 2 years, with the latest figure at $300000.0 in Q4 2025.

  • Quarterly Interest Expenses rose 200.0% year-over-year to $300000.0 in Q4 2025, while the trailing twelve-month figure through Sep 2025 was $4.1 million (changed N/A YoY) and the FY2025 annual result came in at $12.6 million, up 1.11% from the prior year.
  • Interest Expenses declined to $300000.0 in Q4 2025 per MPLT's latest filing, from $4.1 million in the prior quarter.
  • Over five years, Interest Expenses peaked at $4.1 million in Q3 2025 and troughed at -$300000.0 in Q4 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int Expense (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 439.40 Mn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 52.50 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - 2.70 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 39.74 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 335,572.77
7 Royalty Pharma 33.72 Bn 35.84 Bn - 218.10 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 82.05 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 20.27 Mn
10 MapLight Therapeutics 533.88 Mn 533.88 Mn - 91.13 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 91.13 Mn
Jun 30, 2026 91.13 Mn
Dec 31, 2025 300,000.00
Dec 31, 2025 300,000.00
Sep 30, 2025 4.12 Mn
Sep 30, 2025 4.12 Mn
Dec 31, 2024 -300,000.00
Dec 31, 2024 -300,000.00
Sep 30, 2024 300,000.00
Sep 30, 2024 300,000.00